McAllister, Peter
Winner, Paul K.
Ailani, Jessica
Buse, Dawn C.
Lipton, Richard B.
Chakhava, George
Josiassen, Mette Krog
Lindsten, Annika
Mehta, Lahar
Ettrup, Anders
Cady, Roger
Funding for this research was provided by:
H. Lundbeck A/S
Article History
Received: 11 November 2021
Accepted: 20 December 2021
First Online: 7 February 2022
Declarations
:
: Approval for each study was provided by the independent ethics committee or institutional review board of the study sites. The studies were each conducted in accordance with Good Clinical Practice guidelines, the principles of the Declaration of Helsinki, and all applicable regulatory requirements. Patients provided written informed consent prior to initiation of any study procedures.
: Not applicable.
: PM reported receiving personal fees and research support from Abbvie, Amgen/Novartis, Biohaven, Lilly, Lundbeck, and Teva.PKW reported receiving consulting fees from Abbvie, Amgen, Biohaven, Lilly, Lundbeck, Novartis, Teva; serving on speaker bureaus for Abbvie, Amgen, Biohaven, Lilly, Lundbeck, Novartis, Teva; and receiving research support from Abbvie, Amgen, AZ, Biogen, Lilly, Lundbeck, Novartis, Supernus, Teva.JA reported receiving clinical trial grants from Abbvie, Biohaven, Lilly, Satsuma, and Zosano; consulting fees from Abbvie, Amgen, Axsome, Biohaven, electroCore, Impel, Lilly, Lundbeck, Revance, Satsuma, Theranica, and Vorso; and speaker fees from Abbvie, Amgen, Biohaven, Impel, Lilly, Lundbeck, and Satsuma.DCB has received grant support from Amgen, the National Headache Foundation, and the FDA; has received consulting support from Allergan/Abbvie, Amgen, Lilly, Lundbeck, and Teva; and serves on the editorial board of <i>Current Pain and Headache Reports.</i>RBL receives or has received, as a consultant and/or advisory panel member, honoraria from Lundbeck Seattle BioPharmaceuticals, Allergan, American Academy of Neurology, American Headache Society, Amgen, Biohaven Pharmaceuticals, BioVision, Boston Scientific, Dr. Reddy’s Laboratories, electroCore Medical, eNeura Therapeutics, GlaxoSmithKline, Lilly, Merck, Pernix, Pfizer, Supernus, Teva Pharmaceuticals, Trigemina, Vector, and Vedanta; received compensation from eNeura and Biohaven Pharmaceuticals, has stock or stock options in Biohaven Pharmaceuticals and Manistee; receives research support from Amgen, Migraine Research Foundation, and National Headache Foundation.GC had nothing to declare.MKJ, AL, and AE are employees of Lundbeck or one of its subsidiary companies.LM was an employee of Lundbeck Seattle BioPharmaceuticals at the time of study. RC was an employee of Lundbeck or one of its subsidiary companies at the time of study and manuscript development.